ÃâÒßѧÊÔÌâ
2s{P
E Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
N;cEf7+f 1. Fas(CD95)/FasL
U$[C>~ r 2. common chain of cytokine receptor
\\80c65- 3 . TCR/CD3 complex
O j<.3U[C 4. negaive selection of thymocytes
+@]b}W 5. artificial active immune
>hcA:\UPk 6. anti-idiotypic
Mg
H,"G 7. IgSF
R u^v!l`!7 8. Integrin
2c>e Mfa 9. chemokine
M)Iu' 10. B7/CD28
}`g:)gJ ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©
S Rs~p 1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£
BJI}gm2y 2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£
{R[FwB^7wJ 3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£
i6R2R8 5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½
B4^+&B#
]3@6o*R; 1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£
=M"H~;f] µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ
P-9[,3Zd Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
"(y",!U@ 1. B7/CD28
w9
I7pIIl 2. Th1 subset
a!MhxM5 3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£©
BIf E+L( 4. antibody affinity maturation
`Tt}:9/3 5. AP-1
.Ap-<FB 6. single chain variable fragment£¨ScFv£©
Fw!wSzsk3 7. NK cell receptor
qbjBN z 8. Zinkernagel-Doherty phenomenon
%"GF+ 9. Ig fold
^R* _Q,o# 10. CD40/CD40L
$mvcqn; ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£©
(4_7ICFI 1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£
|FZ)5 2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿
;K<e]RI;? 3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿
<
aeBhg
% Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩
Zw+VcZz3 1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£
8Xpf|?. 2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£
4 4bTx y 3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£
cU8Rm\? Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
s(*LV2fa £¨ÃâÒßѧרҵºÍרҵ»ù´¡£©
nU]n]gd Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©
}
DY{> D> 1.Co-stimulators (or co-stimulating molecules)
cW B
> 2.NK-kB
} ).rD 3.Immunoglobulin superfamily
~l$u~:4Ob 4.antigen-presenting cell (APC)
1e`/N+6u 5.death domain
( ONn{12Q 6.CCR and CXCR
"?Dov/+Q. 7.Lectin (or mitogen)
%H=d_Nm{ 8.Clusters of differentiation, CD)
9(?9yFbj5 9.B7 family
)cA#2mlS'1 10.Cytotoxic T lymphocyte, CTL)
C/Vs+aW
n 11.IL-15 and IL-15 receptor (IL-15R)
gL%%2 }$ 12.MHC restriction
*0>![v 13.Affinity-chromatography
KL:x!GsV5e 14.Cyctosprin A, CsA
%:I\M)t}k 15.Antibody-dependent cell-mediated cytotoxicity, ADCC)
_'9("m V ¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©
$hexJzX 1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿
9kmEg$WM 2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£
Xup rl2+ 3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£
$4K(AEt[ Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©
Oax*3TD ÃâÒßѧרҵ£º
Xv[5)4N 1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£
yuyI)ebC Ïû»¯ÄÚ¿Æ£º
hV5Aw;7C 2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£
I9S=VFhZ` ѪҺ²¡Ñ§×¨Òµ£º
~{Gbu oH 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿
m80e^ Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
4DhGp (רҵ»ù´¡: ÃâÒßѧ)
RbPD3&. Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)
<9zzjgzG{c 1. ADCC(antibody dependent cell-mediated cytotoxicity)
}j=UO*| 2. »·æß¾úËØ(cyclosporin)
oNW.-gNT 3. KIR(killer cell inhibitory receptor)
!|!k9~v! 4. HLDA(human leucocyte differentiation antigen)
a!UQ]prT 5. Interleukin 18(IL-18)
a?Q\nu1 6. ÕûºÏËØ(integrin)
0ws1S(pq 7. Fas/FasL
Z>=IP-,> 8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)
ITcgpK6k 9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)
9a\H+Y~ 10. Th1/Th2
;bz|)[4/ 11. »ùÒòÒßÃç(DNAÒßÃç)
<sU?q<MC 12. chemokines and chemokine receptor
yVF1*#" 13. ÃâÒßÄÍÊÜ
E
P1f6ps 14. ¹²´Ì¼¤·Ö×Ó
gcS?r : 15. ËÀÍö½á¹¹Óò(death domain)
N=Q<mj;, ¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)
GnAG'.t-Z 1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?
%:yp>nm 2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óá£
%S$P<nKN5 £¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î
0tA
~Y26 £¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
P
X9GiJN " £¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå
x9l l 0Ht £¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹
GvAP 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£
ALcin))+B Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ)
UCu0
Xqf ÎÊ´ðÌâ(ÿÌâ25·Ö)
l=|>9,La 1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£
0H$6_YX4A 2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿
q fc:%ks2 3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£
GtuA94=!V& 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£